南非国家可及性规划中含氟胞嘧啶联合方案治疗隐球菌性脑膜炎的结局:横断面观察性研究
该横断面观察性研究在南非19家哨点医院比较了含氟胞嘧啶诱导方案与其他方案治疗成人实验室确诊隐球菌性脑膜炎的结局。1539例接受抗真菌治疗的患者中,596例(38.7%)使用含氟胞嘧啶方案,943例(61.3%)使用其他方案。含氟胞嘧啶组院内粗病死率为23.9%(95%CI 20.0-27.0),其他方案组为37.2%(95%CI 34.0-40.0);校正混杂因素后,氟胞嘧啶治疗与死亡率降低53%相关(aOR 0.47,95%CI 0.35-0.64;p<0.0001)。
要点
- 含氟胞嘧啶方案组院内粗病死率23.9%(143/596),其他方案组37.2%(351/943)。
- 校正混杂因素后,氟胞嘧啶治疗与死亡率降低53%相关(aOR 0.47,95%CI 0.35-0.64;p<0.0001)。
- 幸存者中,含氟胞嘧啶组中位住院时间11天(IQR 8-15),其他方案组17天(IQR 13-21)(p=0.0010)。
核心结论
- 含氟胞嘧啶方案治疗的患者院内死亡率与近期一项多中心非洲临床试验中接受含氟胞嘧啶方案的患者所报告的降低死亡率相当。
- 含氟胞嘧啶的治疗可在中等收入国家的常规诊疗中实施,并带来实质性生存获益。
研究设计与样本
- 横断面观察性研究,比较南非19家哨点医院中18岁及以上成人实验室确诊隐球菌性脑膜炎患者接受含氟胞嘧啶方案与否的结局。
- 2018年7月1日至2020年3月31日期间,10668例实验室确诊隐球菌性脑膜炎患者中,排除非增强监测点诊断的7787例和无氟胞嘧啶可及的8个增强监测点的567例后,19家氟胞嘧啶可及机构诊断的2314例成人中1996例有病例报告表,其中1539例接受诱导抗真菌治疗且为HIV血清阳性的首次发作病例纳入分析。
- 采用随机效应逻辑回归分析治疗组与院内死亡率之间的关联。
主要发现
- 1539例接受抗真菌治疗的患者中,596例(38.7%)接受含氟胞嘧啶方案,943例(61.3%)接受其他方案;中位年龄36岁(IQR 32-43),男性906例(58.9%),女性633例(41.1%)。
- 含氟胞嘧啶方案组院内粗病死率为23.9%(95%CI 20.0-27.0;143/596),其他方案组为37.2%(95%CI 34.0-40.0;351/943)。
- 非学术医院收治的患者(aOR 1.95,95%CI 1.53-2.48;p<0.0001)和抗逆转录病毒治疗经治者(aOR 1.30,95%CI 1.02-1.67;p=0.033)更可能接受氟胞嘧啶。
- 校正相关混杂因素后,氟胞嘧啶治疗与死亡率降低53%相关(aOR 0.47,95%CI 0.35-0.64;p<0.0001)。
- 幸存者中,含氟胞嘧啶组中位住院时间为11天(IQR 8-15),其他方案组为17天(IQR 13-21)(p=0.0010)。
关键数值与推荐
- 隐球菌病病例定义为成人患者具备以下任一条件:脑脊液墨汁染色显微镜检查阳性;脑脊液隐球菌抗原试验阳性;或从脑脊液或其他标本培养出新型隐球菌(Cryptococcus neoformans)或格特隐球菌(Cryptococcus gattii)。
- 排除无病例报告表、HIV血清学结果未知或阴性、复发发作、以及未在医院接受抗真菌治疗的患者。
临床怎么用
- 作者认为,含氟胞嘧啶的治疗可在中等收入国家的常规诊疗中实施,并带来实质性生存获益。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although flucytosine is a key component of WHO-recommended induction treatment for HIV-associated cryptococcal meningitis, this antifungal agent is not widely available in low-income and middle-income countries due to limited production and cost. In 2018, a national flucytosine access programme was initiated in South Africa. We aimed to determine the effectiveness of flucytosine-containing induction regimens in routine care to motivate for the urgent registration of flucytosine and its inclusion in treatment guidelines. METHODS: In this cross-sectional study, we compared outcomes of adults aged 18 years and older with incident laboratory-confirmed cryptococcal meningitis treated with or without flucytosine-containing regimens at 19 sentinel hospitals in South Africa. A case of cryptococcosis was defined as illness in an adult with: (1) positive cerebrospinal fluid (CSF) India ink microscopy; (2) a positive CSF cryptococcal antigen test; or (3) culture of Cryptococcus neoformans or Cryptococcus gattii from CSF or any other specimen. We excluded patients without a case report form, those with an unknown or negative HIV serology result, those with a recurrent episode, and those who did not receive antifungal treatment in hospital. We assessed cumulative in-hospital mortality at 14 days and 30 days and calculated the overall crude in-hospital case-fatality ratio. We used random-effects logistic regression to examine the association between treatment group and in-hospital mortality. FINDINGS: From July 1, 2018, to March 31, 2020, 10 668 individuals were diagnosed with laboratory-confirmed cryptococcal meningitis, 7787 cases diagnosed at non-enhanced surveillance sites and 567 cases from eight enhanced surveillance sites with no access to flucytosine were excluded. Of 2314 adults with a first episode of cryptococcosis diagnosed at 19 facilities with access to flucytosine, 1996 had a case report form and of these, 1539 received induction antifungal treatment and were confirmed HIV-seropositive first-episode cases. Of 1539 patients who received antifungal therapy, 596 (38·7%) individuals received a flucytosine-containing regimen and 943 (61·3%) received another regimen. The median age was 36 years (IQR 32-43) and 906 (58·9%) participants were male and 633 (41·1%) were female. The crude in-hospital case-fatality ratio was 23·9% (95% CI 20·0-27·0; 143 of 596) in those treated with flucytosine-containing regimens and 37·2% (95% CI 34·0-40·0; 351 of 943) in those treated with other regimens. Patients admitted to non-academic hospitals (adjusted odds ratio [aOR] 1·95 [95% CI 1·53-2·48]; p<0·0001) and those who were antiretroviral treatment-experienced (aOR 1·30 [1·02-1·67]; p=0·033) were more likely to receive flucytosine. After adjusting for relevant confounders, flucytosine treatment was associated with a 53% reduction in mortality (aOR 0·47 [95% CI 0·35-0·64]; p<0·0001). Among survivors, the median length of hospital admission in the flucytosine group was 11 days (IQR 8-15) versus 17 days (13-21) in the comparison group (p=0·0010). INTERPRETATION: In-hospital mortality among patients treated with a flucytosine-containing regimen was comparable to reduced mortality reported in patients receiving a flucytosine-containing regimen in a recent multicentre African clinical trial. Flucytosine-based treatment can be delivered in routine care in a middle-income country with a substantial survival benefit. FUNDING: National Institute for Communicable Diseases, a Division of the National Health Laboratory Service. TRANSLATION: For the Zulu translation of the abstract see Supplementary Materials section.
引用
- Mashau RC, Meiring ST, Quan VC, et al. Outcomes of flucytosine-containing combination treatment for cryptococcal meningitis in a South African national access programme: a cross-sectional observational study. Lancet Infect Dis. 2022. PMID: 35750065. doi:10.1016/S1473-3099(22)00234-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。